Posterior reversible encephalopathy syndrome following pembrolizumab therapy for relapsed Hodgkin’s lymphoma

LaPorte, Justin; Solh, Melhem; Ouanounou, Serge

doi:10.1177/1078155215620922

Cited by 31 publications

(11 citation statements)

References 10 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Of particular note are reports of immune‐mediated encephalitis because of its potentially fatal nature , as well as two cases of posterior reversible encephalopathy syndrome and acute encephalopathy toxicity, respectively , seen with nivolumab, pembrolizumab, and ipilimumab.…”

Section: Introductionmentioning

confidence: 99%

Neurologic Serious Adverse Events Associated with Nivolumab Plus Ipilimumab or Nivolumab Alone in Advanced Melanoma, Including a Case Series of Encephalitis

et al. 2017

View full text Add to dashboard Cite

With increasing use of checkpoint inhibitors in cancer, practicing oncologists need to be aware of the potential risk of neurologic immune-related adverse events and be able to provide prompt treatment of this uncommon, but potentially serious, class of adverse events. We summarize neurologic adverse events related to nivolumab alone or in combination with ipilimumab in patients with advanced melanoma from 12 studies and examine in depth 6 cases of encephalitis. We also provide input and guidance on the existing neurologic adverse events management algorithm for nivolumab and ipilimumab.

show abstract

Section: Introductionmentioning

confidence: 99%

Neurologic Serious Adverse Events Associated with Nivolumab Plus Ipilimumab or Nivolumab Alone in Advanced Melanoma, Including a Case Series of Encephalitis

et al. 2017

View full text Add to dashboard Cite

show abstract

“…Recently, several cases of PRES developed in female patients receiving immune checkpoint inhibitors have been reported . Among these, two case reports described high blood pressure at the diagnosis of PRES: 170/90 mm Hg in a patient receiving ipilimumab for melanoma treatment and 148/95 mm Hg in a patient receiving nivolumab for lung cancer .…”

Section: Discussionmentioning

confidence: 99%

“…Recently, several cases of immunotherapy‐related PRES have been reported as a rare cause of PRES in patients receiving ipilimumab, a monoclonal antibody against cytotoxic T‐lymphocyte‐associated protein 4 (CTLA‐4), both ipilimumab and nivolumab, nivolumab alone, or pembrolizumab . Here, we present a case of PRES occurring in a male patient receiving nivolumab for treating non–small‐cell lung cancer.…”

Section: Introductionmentioning

confidence: 95%

Posterior reversible encephalopathy syndrome induced by nivolumab immunotherapy for non–small‐cell lung cancer

Kim

2019

Clinical Case Reports

View full text Add to dashboard Cite

Key Clinical Message Posterior reversible encephalopathy syndrome (PRES) is a neurological syndrome characterized by vasogenic cerebral edema with predominantly posterior involvement. Uncontrolled severe hypertension and endothelial dysfunction have been implicated as two main mechanisms. Clinicians should notice the development of PRES in hypertensive patients accompanying neurological changes, such as impaired vision and consciousness.

show abstract

“…Central neurological adverse events have also been seen with checkpoint blockade including immune mediated encephalitis (54), aseptic meningitis (53), and posterior reversible encephalopathy syndrome (PRES) (55,56). Symptoms are wide ranging and can include altered mental status, headaches, fevers, confusion, receptive and expressive aphasia, and motor or sensory changes.…”

Section: Neurologic and Ocular Toxicitiesmentioning

confidence: 99%

Identifying and managing the adverse effects of immune checkpoint blockade

Winer¹,

Bodor²,

Borghaei³

2018

J. Thorac. Dis.

View full text Add to dashboard Cite

Immunotherapy has revolutionized the field of oncology. By inhibiting the cytotoxic T-lymphocyte-associated protein (CTLA-4) and programmed death-1 (PD-1) immune checkpoint pathways, multiple studies have demonstrated greatly improved survival in locally advanced and metastatic cancers including melanoma, renal, lung, gastric, and hepatocellular carcinoma. Trials in other malignancies are ongoing, and undoubtedly the number of drugs in this space will grow beyond the six currently approved by the Food and Drug Administration. However, by altering the immune response to fight cancer, a new class of side effects has emerged known as immune-related adverse events (irAEs). These adverse events are due to overactivation of the immune system in almost any organ of the body, and can occur at any point along a patient's treatment course. irAEs such as endocrinopathies (thyroiditis), colitis, and pneumonitis may occur more commonly. However, other organs such as the liver, heart, or brain may also be affected by immune overactivation and any of these side effects may become life threatening. This review presents an approach to promptly recognize and manage these toxicities, to hopefully minimize morbidity and mortality from irAEs.

show abstract

Posterior reversible encephalopathy syndrome following pembrolizumab therapy for relapsed Hodgkin’s lymphoma

Cited by 31 publications

References 10 publications

Neurologic Serious Adverse Events Associated with Nivolumab Plus Ipilimumab or Nivolumab Alone in Advanced Melanoma, Including a Case Series of Encephalitis

Neurologic Serious Adverse Events Associated with Nivolumab Plus Ipilimumab or Nivolumab Alone in Advanced Melanoma, Including a Case Series of Encephalitis

Posterior reversible encephalopathy syndrome induced by nivolumab immunotherapy for non–small‐cell lung cancer

Identifying and managing the adverse effects of immune checkpoint blockade

Contact Info

Product

Resources

About